Ethical Issues of Using Gene Therapy in the Treatment of AMD

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 30

Sponsor: Nantes University Hospital

Summary

The objective of this study is to examine the legitimacy of gene therapy use in the treatment of exudative age-related macular degeneration (AMD). This involves questioning its beneficence/non-maleficence ratio given the limited experience with this innovative technology and its irreversible effects, requiring a surgical procedure for administration. Additionally, the study explores patient autonomy in decision-making concerning complex therapeutic approaches and how patients should be supported to best uphold this autonomy.

Eligibility Criteria

Inclusion Criteria: * Patients with exsudative AMD, male female \>18 years Patients for whom the doctor could consider gene therapy. Exclusion Criteria: Patients with atrophic AMD (Age-related Macular Degeneration) Patients with other degenerative retinal diseases than AMD, Patients with with associated cognitive disorders.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07004361). StuddyBuddy aggregates publicly available trial information.